The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has made the following purchases of ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") (the “Purchases”):
| Date | Ordinary Shares purchased | Price paid per Ordinary Share (p) |
|---|---|---|
| 5th May 2017 | 1,117 | 4.8 |
| 8th May 2017 | 100,000 | 5.0 |
| 9th May 2017 | 100,000 | 5.0 |
Following the Purchases Vulpes has a total direct and indirect interest in 54,346,401 equivalent to 18.44% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,346,401 Ordinary Shares of the Company representing 18.44% of the issued share capital of the Company.